| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 322.34M | 447.86M | 623.98M | 725.35M | 496.69M | 445.19M |
| Gross Profit | 105.81M | 162.31M | 224.67M | 125.21M | -2.92M | 43.77M |
| EBITDA | 54.35M | 30.90M | 113.06M | 131.09M | -117.87M | 72.03M |
| Net Income | 30.43M | 4.65M | 78.89M | 100.95M | -151.56M | 46.90M |
Balance Sheet | ||||||
| Total Assets | 364.91M | 332.61M | 598.19M | 666.19M | 560.40M | 704.23M |
| Cash, Cash Equivalents and Short-Term Investments | 25.61M | 31.60M | 107.64M | 143.61M | 95.12M | 116.28M |
| Total Debt | 55.87M | 18.94M | 723.00K | 98.85M | 109.82M | 117.83M |
| Total Liabilities | 166.65M | 123.16M | 161.92M | 266.62M | 249.90M | 232.37M |
| Stockholders Equity | 198.26M | 209.45M | 436.27M | 398.21M | 309.13M | 470.72M |
Cash Flow | ||||||
| Free Cash Flow | 8.01M | 22.69M | 75.22M | 63.72M | -8.76M | 36.18M |
| Operating Cash Flow | 26.65M | 45.68M | 109.86M | 97.63M | 15.83M | 54.96M |
| Investing Cash Flow | -34.96M | -46.74M | -18.00M | -29.62M | -19.22M | -15.28M |
| Financing Cash Flow | 6.07M | -75.52M | -125.66M | -18.99M | -17.98M | -15.62M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | CHF1.72B | 44.07 | ― | 0.68% | 27.24% | 122.39% | |
60 Neutral | CHF59.51M | 24.05 | ― | 1.40% | -4.53% | 43.42% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% | |
54 Neutral | CHF403.17M | 13.24 | ― | 2.98% | -45.71% | 215.99% | |
52 Neutral | CHF10.04M | -1.21 | ― | ― | -13.04% | -1151.20% | |
44 Neutral | CHF1.15B | 550.61 | ― | ― | 9.72% | ― |
CPH Group AG has adjusted its earnings forecast for 2025, anticipating an EBITDA of CHF 50 million, lower EBIT, and a reduced net result due to challenges in the global pharmaceutical packaging market, unfavorable exchange rates, and increased costs. Despite these challenges, the company expects revenue to remain above the previous year and continues to focus on cost reductions and process optimizations to improve profitability. The company remains optimistic about its medium-term growth prospects, driven by trends in health, demographics, and energy, and expects stable business development and positive earnings in 2026.